Phase I and pharmacokinetic (PK) study of irinotecan (CPT-11) and amrubicin (AMR) in non-small cell Lung Cancer (NSCLC)

Authors :: N. Yanase
Sayaka Onoda
Noriyuki Masuda
E. Kato
Hisashi Mitsufuji
Shinichiro Ryuge
S. Hagiri
Mayuko Wada
Tomoko Yanaihara
Michiko Yamamoto
Source :: Journal of Clinical Oncology. 23:2070-2070
Publication Year :: 2005
Publisher :: American Society of Clinical Oncology (ASCO), 2005.
Abstract: 2070 Background: CPT-11 (topoisomerase I inhibitor) and AMR (topoisomerase II inhibitor) are active against several solid tumors including NSCLC. Based on the preclinical data, this phase I trial w...

Subjects :: Cancer Research
business.industry
non-small cell lung cancer (NSCLC)
Topoisomerase-I Inhibitor
medicine.disease
Preclinical data
Irinotecan
Oncology
Pharmacokinetics
Cancer research
medicine
Topoisomerase-II Inhibitor
Nuclear medicine
business
neoplasms
Amrubicin
medicine.drug

Tools